Intensity modulated radiation therapy (IMRT) has achieved widespread use for prostate cancer; however, in relation to this use, outcomes studies are still relatively sparse. We report a single-institutional experience in outcomes analysis with the use of IMRT for the primary management of prostate cancer. One hundred thirty consecutive patients with adenocarcinoma of the prostate were treated at a single institution using IMRT with curative intent. Thirty-six (28%) patients were classified as low-risk, 69 (53%) as intermediate-risk, and 25 (19%) as high-risk. The median dose prescription was 76 Gy to the planning target volume. Sixty-five (50%) patients received androgen deprivation therapy (ADT) for a median 4 months, starting 2 months prior to IMRT. Biochemical failure was defined as PSA > post-treatment nadir+2. Gastrointestinal (GI) and Genitourinary (GU) toxicity were defined by RTOG criteria. Median follow-up was 53 months. By NCCN risk category, 4-year biochemical control was 97%, 94%, and 87% for low, intermediate, and high-risk patients, respectively. Among disease factors, multivariable analysis demonstrated the strongest association between biochemical control and Gleason score ≤6 (p=0.0371). Therapy was well tolerated with no Grade 4 toxicity and limited grade 3 GI or GU toxicity. Acute Grade 3+ GI and GU toxicity rates were 0% and 2%, and maximal late Grade 3+ GI and GU toxicity rates were 5% and 6%, respectively. Late rectal toxicity was associated with higher volumes of RT to the rectum. By last follow-up late Grade 3+ toxicity was 2% for both GI and GU systems. In conclusion, patients treated with IMRT for prostate cancer have excellent rates of biochemical control and low rates of severe toxicity of treatment.
Introduction
External beam Radiation Therapy (RT) is an excellent non-invasive treatment option for patients with localized or locally advanced prostate cancer. Biochemical control with RT compares favorably with radical prostatectomy for localized disease, as long as the radiation dose is sufficiently high (1, 2). As a means to treat prostate cancer with dose-escalated RT, yet reduce the volume of surrounding normal tissue that receives high doses of RT, Intensity-Modulated Radiation Therapy (IMRT) has been in use for part of the last decade. Despite its widespread use in practice today, there are relatively few reports of biochemical control and late toxicity in the literature with follow-up beyond 3 years (3) (4) (5) (6) (7) (8) . The purpose of this study is to report the experience of using IMRT to treat prostate cancer for a cohort of men observed with a minimum 5 years of potential follow-up.
Methods
Five-hundred twenty-two patients were treated at the University of Chicago Hospitals with curative-intent, external beam RT between 1988 and 2004 for non-metastatic prostate cancer. No patients had prior prostatectomy or combination radioactive seed implant. Within this group, 130 consecutive patients were identified who were treated with IMRT for their entire course of radiation therapy. Virtually all prostate cancer patients from 2001 onwards were treated with IMRT. Patient data, including demographic, disease, and treatment information was recorded, and follow-up information was updated prospectively; review of these outcomes was performed with Institutional Review Board approval.
Patient characteristics are included in Table I . Pretreatment urinary symptoms were documented by the International Prostate Symptom Score (IPSS), with median score 7 (range, 0-32) in 129 patients. In this survey, median urinary quality of life score was 2. By National Comprehensive Cancer Network risk classification guidelines, there were 36 (28%) low-risk patients, 69 (53%) intermediate-risk patients, and 25 (19%) high-risk patients. Patients underwent computed tomography (60%, 48/125) and/or bone scan (28%, 35/123) for high-risk features. No patients in this cohort had radiographic disease in the pelvic lymph nodes. Sixty-five (50%) patients received androgen deprivation therapy (ADT), given for a median four months, typically timed to start two months prior to RT. ADT consisted of combined androgen blockade with an oral anti-androgen in combination with a luteinizing hormone-releasing hormone agonist. Only two patients received ADT longer than 9 months, and none for longer than 17 months total.
Patients underwent a treatment planning simulation prior to starting RT. Patients were set up in the supine position, approximately two hours after having taken an enema to empty the rectal contents. Computed tomography (CT) images were acquired at 3 mm slices after infusion of rectal contrast, bladder contrast, and performance of an urethrogram to help define the location of the genitourinary diaphragm. Target volumes and organs at risk were delineated by a single physician over this time period. The planning target volume (PTV) was defined as a 1 cm expansion around the clinical target volume (CTV). With the introduction of image guided radiation therapy (daily ultrasound), the CTV was reduced to 6 mm posteriorly. Organs at risk included the rectum, contoured as a single structure around the rectal wall from the ischial tuberosities to the sigmoid flexure, and the bladder, contoured as a single structure around the bladder wall.
The dose prescription was 74 Gy for low-risk prostate cancer and 76 Gy for intermediate or high-risk prostate cancer. The dose for low-risk prostate cancer was chosen based on the perceived risk/benefit ratio favoring a lower dose for patients with less aggressive disease. Although today we typically prescribe doses of 78 Gy for intermediate-and high-risk patients, many patients in this study were treated before major randomized dose escalation studies were reported. Patients were treated using 2 Gy daily fractions. The initial CTV was prostate and proximal seminal vesicles in 125 (96%) patients, the pelvic lymph nodes in 4 (3%) patients, and prostate alone in 1 patient (1%). The use of whole pelvic RT was not prospectively defined, but generally applied for men at the highest risk of lymph node risk (e.g., clinical T3 disease; >35% risk of involvement). The initial volume was treated to 50-50.4 Gy, and was followed by a 24-26 Gy boost to the prostate alone. Treatment planning was done using Corvus inverse-planning software (Nomos, North American Scientific, Cranberry Township, PA) without heterogeneity corrections. Prioritization was given towards covering the entire target volume; secondary consideration was given towards sparing the organs at risk (rectum, bladder). For purposes of dosevolume histogram (DVH) analysis, use of a separate planning system was necessary because the Corvus treatment planning system does not allow any voxel to belong to more than one structure. True DVH's were generated for the bladder and rectum and were subsequently used in plan evaluation.
The volume of PTV receiving the full prescription dose (V100%) was a minimum of 97%, and median 98.7%. Median V105% to the PTV was 75% and median maximal dose was 83.4 Gy (or 110% of the prescription dose). The maximum hot spot to any voxel was limited to <115% of the pre-scription dose. The mean dose to the PTV was a median 80 Gy. The higher mean dose relative to the prescription dose reflects the inhomogeneity of this IMRT planning software, which resulted in a mean dose that was typically 105% of the prescription dose. Dose constraints on the rectum included V70 Gy (percent of rectal volume receiving 70 Gy) < 20% and V40 Gy < 60%. Hot spots were limited over rectal tissue as best as possible. Absolute dose constraints to the bladder were not observed for plan approval; sparing of dose to the bladder was secondary to adequate coverage of the PTV and sparing of the rectum over the time period of this study. The median values for rectal V75 Gy (percent of rectal volume receiving 75 Gy), V70 Gy, V65 Gy, and V40 Gy were 8%, 14%, 19%, and 57%, respectively. Median values for similar bladder parameters were 10%, 14%, 18%, and 48%, respectively. The median rectal and bladder volumes were 99 cc and 156 cc, respectively.
Patients were set up for treatment according to bony anatomy until April 2003, after which point transabdominal ultrasound was introduced to localize the prostate prior to daily treatment. Implanted fiducial markers were not used over the time period of study, although this is the current method of daily prostate localization at our institution. Treatment was delivered using 6 MV photons with 5, 7, or 9 coplanar fields using step-and-shoot IMRT. Typical beam angles for a 7-field plan were 0, 40, 80, 120, 240, 280, and 320 degrees, where 0 degrees is an anterior beam. No posterior beams were used in an attempt to produce a sharper dose gradient through the rectum.
Patients were seen in follow-up one month after completion of RT, at intervals of 3-9 months for the first five years, and yearly thereafter. The median potential follow-up time (time from end of RT to time of data analysis) for patients in this cohort was 73 months (range, 60-89), while follow-up from completion of RT to last follow-up was a median 53 months. By risk category, median follow-up was 56, 51, and 44 months, for low, intermediate, and high-risk disease, respectively. Toxicity was defined using Radiation Therapy Oncology Group (RTOG) criteria for gastrointestinal (GI) and genitourinary (GU) systems. In this scoring system, grade 1 toxicity involves minimal side effects not requiring medications. Grade 2 toxicity is defined as moderate symptoms, requiring the use of any medical therapy (e.g., prescription medications for urinary frequency or hematochezia) for side effects of treatment. Grade 3 toxicity involves severe symptoms requiring the use of a procedure to address symptoms (e.g., dilation for urinary stricture, cauterization for hematochezia, transfusion). Grade 4 toxicity is major, life-threatening requiring major surgery or hospitalization. Any toxicity greater than 3 months after completion of RT was considered late toxicity. Hematochezia from hemorrhoids was excluded as an RT side effect. The use of endoscopy or cystoscopy for evaluation of bleeding was not strictly regulated, but was recommended for any patient with intermittent bleeding. Therefore, patients with Grade 2 and higher toxicity typically had confirmation of bleeding from a source felt to be consistent with radiation cystitis or proctitis.
Freedom from biochemical failure (FFBF) was defined according to the Phoenix definition (9) (failure at the time that PSA is 2 ng/mL greater than absolute post-treatment nadir). Secondary analysis was performed with the ASTRO consensus definition (10) (failure occurs with three consecutive PSA rises with time of failure backdated prior to first rise) for comparison to historical standards. The ASTRO failure was coded using a program made available by Williams et al. (11) . Kaplan-Meier analysis was used to estimate biochemical control. Chi-square analysis was used for univariate analysis to assess whether common prognostic factors (PSA, Gleason score, T stage, ADT) were associated biochemical outcome (Phoenix definition). Proportional hazards regression was used to test these same factors in multivariable analysis to define clinical and treatment parameters associated with biochemical control. Univariate analysis was performed to test age, pretreatment IPSS, prostate volume, RT dose, and ADT against late Grade 2+ toxicity. Dose-volume parameters were also tested against GI or GU toxicity, including V75 Gy, V70 Gy, V65 Gy, V40 Gy, and overall volume of the rectum or bladder, respectively. These doses were chosen for analysis to represent both high and medium doses to the normal tissues. Analysis was performed by converting continuous variables in binary variables stratified by the median value unless otherwise noted. For multivariable analysis of late toxicity, only those factors that were associated with Grade 2+ toxicity on univariate analysis (p<0.10) were used as covariates. Figure 1 , by risk category. Using the Phoenix definition, rates of biochemical control at 4-years were 97%, 94%, and 87% for low, intermediate, and highrisk patients. Using the ASTRO definition, rates of biochemical control at 4-years were 85%, 77%, and 82% for low, intermediate, and high-risk patients.
Results

FFBF is indicated in
Univariate analysis demonstrated that patients with Gleason score ≤6 disease had improved biochemical outcome (4-y FFBF 97% vs 90%, p=0.0582). Other tested factors including T stage (stratified by ≥T2A, p=0.3648), PSA (stratified by median PSA, p=0.6660), and ADT use (p=0.9512) were not independently associated with FFBF. Multivariable analysis (Table II) indicated that Gleason score was associated with biochemical control, whereas T stage, PSA value, and ADT were not. One patient developed distant metastasis 9 months after completion of RT, and died 19 months thereafter. Cause-specific survival at 4-years was 99%, and overall survival at 4-years was 97%.
Crude incidences of acute and late toxicity for GI and GU systems are shown in Table III . No patient had Grade 4 toxicity. Grade 3 toxicity was uncommon, with 2% of patients experiencing acute grade 3 GU toxicity and no patients experiencing acute grade 3 GI toxicity; 5-6% of patients experienced late grade 3 GI or GU toxicity. By actuarial analysis at 4-years, the rate of maximal Grade 3+ GI toxicity was 5%, and Grade 3+ GU toxicity was 6%. At time of last follow-up, the rate of Grade 3+ GI and GU toxicities was lower, at 2% each. IPSS score and urinary quality of life score at last follow-up were not significantly different from pretreatment IPSS score (p=0.7293 and p=1.000, respectively, by paired t-test). The median IPSS score at last follow-up was 6 (range, 0-24) with urinary quality of life score 2.
Univariate analysis was performed testing a number of factors (stratified by the median values) against the rate of late Grade 2+ GI toxicity. Age (p=0.2143), prostate volume (p=0.8861), ADT (p=0.7945), and rectal volume (p=0.3515) were not associated with late Grade 2+ GI toxicity. RT dose was associated with late toxicity, with 19% of men with dose ≥76 Gy with Grade 2+ GI toxicity versus 0% in men with dose <76 Gy (p=0.0004). DVH parameters were also tested against late GI toxicity, including V75 Gy, V70 Gy, V65 Gy, and V40 Gy (stratified by the median values) to the rectum. Rectal V75 Gy was not associated with late Grade 2+ GI toxicity (p=0.4419). However, a higher V70 Gy (20% vs 8%, p=0.0638), higher V65 Gy (19% vs 7%, p=0.0562), and higher V40 Gy (23% vs 5%, p=0.0023) to the rectum were associated with higher rates of late Grade 2+ GI toxicity.
Because of these associations, a combination of rectal DVH parameters were tested. Patients with rectal V70 Gy < 15%, V65 Gy < 30%, and V40 Gy < 60% (n=55) had a 7% incidence of late Grade 2+ GI toxicity. Patients with rectal V70 Gy < 20%, V65 Gy < 40%, and V40 Gy < 80% (n=54) had a 15% incidence of late Grade 2+ GI toxicity. Patients who did not meet either criteria (n=14) had a 38% incidence of late Grade 2+ GI toxicity (p=0.0270 among the three groups). Multivariable analysis showed that RT dose (p=0.0010) and V40 Gy (p=0.0138) were associated with late GI toxicity, while V70 Gy (p=0.6852) and V65 Gy (p=0.9154) were not.
Univariate analysis was also performed testing a number of factors (stratified by the median values) against the rate of late Grade 2+ GU toxicity. Age (p=0.3222), prostate volume (p=0.9437 by median value), pretreatment IPSS (stratified by median value ≥7, p=0.1395; stratified by ≥15, p=0.2046), RT dose (0=0.9082) and ADT (p=1.000) were not associated with toxicity. However, larger bladder volume was associated with a higher rate of Grade 2+ GU toxicity (44% vs 23%, p=0.0174). Bladder V75 Gy (p=0.5212), V70 Gy (p=0.6553), V65 Gy (p=0.8454), and V40 Gy (p=0.9499) were not associated with late Grade 2+ GU toxicity. To better account for variation in bladder volume at planning study and daily treatment, bladder parameters were analyzed by absolute volume (cc), in addition to volume as a percentage (%, as above). By absolute volume, bladder V75 Gy (p=0.1588), V70 Gy (p=0.1780), V65 Gy (p=0.0836), and V40 Gy (p=0.1789) were not associated with late Grade 2+ GU toxicity. Multivariable analysis showed that overall bladder volume (p=0.0585) was associated with late GU toxicity, while V65 Gy (p=0.3395) was not. In effort to understand why larger bladder volume was associated with increased rate of late GU toxicity, the relationship between prostate and bladder volume was evaluated. Treatment of larger prostates would be expected to result in treatment of more of the bladder neck, which could impact late urinary function. Men with larger bladders had larger prostate glands (p=0.0291), and men with larger prostates had increased GU toxicity (when tested as a continuous variable, p=0.0238). However, a multivariable analysis using continuous, rather than categorical, variables did not demonstrate any association among V65 Gy by cc (p=0.2415), prostate volume (p=0.8840), and bladder volume (p=0.2015) with late GU toxicity. A similar multivariable analysis excluding prostate volume also showed no statistical association for V65 Gy by cc (p=0.1337) or bladder volume (p=0.1853).
Discussion
IMRT is a form of radiation therapy that integrates two key technologies -computer operated multi-leaf collimators, and inverse planning software -to deliver a highly conformal dose distribution. The movement of the multi-leaf collimators, as determined by the planning software, enables differential blocking of various portions of each treatment field, resulting in a non-uniform, or "modulated" intensity within each treatment field. The rationale to use IMRT to treat prostate cancer with external beam radiation therapy is straightforward. Randomized trials indicate that higher doses of RT improve biochemical outcome (12) (13) (14) (15) for prostate cancer. When using conventional or 3-Dimensional Conformal RT (3-D CRT), dose escalation to the prostate comes at the expense of significantly increased risk of adjacent normal tissue damage, particularly to the rectum (16). With IMRT, dose can be delivered conformally to the target area while concurrently observing dose constraints to reduce the amount of normal tissue that receives high doses of radiation. In recent years, IMRT has become an accepted standard of care to treat prostate cancer, based on the gains associated with dose escalation as supported by biochemical control and pathologic response (17), as well as retrospective data that demonstrate a low risk of severe toxicity (3-8). As a result, it is unlikely that a randomized trial comparing IMRT and 3-D CRT would accrue due to the perceived lack of clinical equipoise that would required for such a study.
The data presented here indicate that IMRT is a highly effective treatment for patients with prostate cancer. With doses of 74-76 Gy at 2 Gy/fraction, and a minimum potential follow-up of 5 years, biochemical control rates were excellent for all risk categories of disease. The treatment was also well-tolerated, with a relatively low rate (approximately 5%) of acute or late Grade 3 maximal toxicity. Men with higher Gleason scores had lower rates of biochemical control. T-stage and PSA level were not associated with outcome, perhaps related to the small number of failures in the overall cohort. Among the 36 patients with low-risk disease, there was only one biochemical failure with 74 Gy. Intermediate-risk patients also did well, with six biochemical failures among 69 patients treated with 76 Gy. Hormonal therapy did not appear to influence the rate of biochemical control in intermediate-risk patients (at 4-years, 93% with ADT and 94% without ADT, p=0.3704), although further follow-up is warranted to better address this issue. Of note, the ASTRO consensus definition of biochemical failure (three consecutive PSA rises) is reported for purposes of historical comparison. With this definition, gradual testosterone recovery in patients receiving ADT is more likely to result in false positive biochemical failures as PSA is expected to renormalize to a low, but detectable, value. For example, in the intermediate-risk cohort, 4-year biochemical control rate by the ASTRO definition was 68% with ADT, and 86% without ADT (p=0.0544). The inferior ASTRO biochemical control rate for patients receiving ADT contradicts the data that support its use as a means to improve biochemical and clinical endpoints (18). The Phoenix definition is the currently accepted standard of biochemical control for several reasons; it is a more sensitive and specific measure of clinical outcome, and may also be more applicable to patients treated with concurrent ADT (9, 19) .
The outcomes of this series are similar to other published reports of IMRT for prostate cancer (Table IV) . Among institutions, direct comparison is difficult because there exists significant variation in the patient selection, treatment parameters (such as dose prescription, volume of treatment, use of ADT), and the method of reporting toxicity. In our series, the dose prescription required coverage to the entire target volume at a minimum of 2 Gy/fraction. The Corvus planning software used over the study's time period then generated a treatment plan that resulted in a mean prostate dose of approximately 80 Gy (at 2.1 Gy/fraction). With further follow-up, it will be of interest to see how these data compare to experiences using different fractionation regimens. Larger doses per fraction may be associated with increased biological efficacy of treatment, at some potential cost to normal tissue repair of the surrounding tissue. A randomized trial, RTOG 0415, is accruing to address the purported benefits and risks of using fraction sizes larger than the conventional 1.8 Gy/fraction. Toxicity of treatment in our series was fairly low, with approximately 5% requiring a GI or GU procedure (e.g., cautery for hematochezia or hematuria) to address a radiation-induced complication. Only 2% of patients had any such procedure performed in the time period immediately preceding last follow-up, indicating that a number of late complications are self-limited without persistent severe effect. Analysis of clinical and dosimetric factors associated with late morbidity of treatment suggested that rectal DVH constraints (e.g., rectal V70, V65, and V40 Gy) may help limit the late GI morbidity of treatment. Meanwhile, no DVH parameters were associated with late GU toxicity, but patients with the largest bladder volumes had the highest incidence. This finding may have been subject to confounding by other variables, as demonstrated by further multivariable analysis.
In conclusion, in this report of patients treated with IMRT for prostate cancer, biochemical control was excellent across all risk categories, and severe toxicity of treatment was low. These data substantiate that IMRT is an excellent treatment option for men diagnosed with prostate cancer. With continued advancements in the delivery of radiation therapy since the time period of study, such as with treatment planning software and accuracy of daily prostate localization, outcomes should be expected to remain favorable or better in the current era of IMRT for prostate cancer.
